Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. - Wikidata - wikimedia - TriplyDB

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

http://www.wikidata.org/entity/Q35771163

about

Role of Myeloperoxidase in Patients with Chronic Kidney Disease Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.Complexities of plasma apolipoprotein C-III metabolism Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria.Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results?Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study Impaired postprandial lipemic response in chronic kidney disease.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Multiplexed peptide analysis for kinetic measurements of major human apolipoproteins by LC/MS/MS.Kidney function is associated with an altered protein composition of high-density lipoprotein.Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.

P2860

Q26748996-7924506E-7CF1-4BEC-BD03-3778BD949C43 Q28083619-BA0CF198-741E-4399-BBDD-7C98279F4C8E Q33835707-DA3DFB51-1315-47F1-BA28-71D132703BD5 Q34172178-AD8A6A6F-5E7C-4BCC-AE3E-9B5D6E58D228 Q34662899-68EAB11D-DD45-4DEE-9AD6-C329EE05438A Q34955753-33F3C4E6-2A7E-4192-8D40-D77625E381C6 Q35187726-49C6C9D7-230A-46D1-9FB8-D3D7434D26F1 Q35735742-5AB3F8B2-FBA8-48C6-A13D-B18E9AEE1EC4 Q37017211-A1B4F95A-D432-4E4B-B410-91A40A4EFDF8 Q37254899-9CBC1F34-86C9-4312-8A74-5CE3088D39E8 Q38616263-96D4F8B8-0A5A-4D43-88CE-99EBF89A0523 Q38627350-C01A0ED7-D8D5-432E-841D-87956BFC8512 Q38650168-FD510AB8-0321-4C80-8E0D-EFCF476C34F8 Q43247391-B27F1817-DF16-4575-A2A1-C429DE669C4F

P2860

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

http://www.wikidata.org/entity/Q35771163

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@ast

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@en

type

label

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@ast

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@en

prefLabel

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@ast

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@en

P1433

Q35771163-2E8F31A5-786D-426C-8D96-C8C4768C15BF

P1476

Q35771163-8CE66F79-6EAE-4932-BBEC-2642F35E0B61

P2093

Q35771163-3A61B255-CA1E-41A0-90CF-A03FD5C744EE

Q35771163-3C3DE392-C349-4FEA-98E8-42EE6F64C106

Q35771163-5C3AEF53-A492-44CA-8B59-DEA431F44FE8

Q35771163-8BA6EE59-8815-4223-B0AA-3F468335EA9A

Q35771163-8C695AF1-3D75-48E4-9B9A-18AB6B4EB643

Q35771163-D07FC03E-84AF-40F0-AFDA-14A9241C80DE

Q35771163-DF00A34A-1D0B-462A-9428-0737945D0647

Q35771163-FC15B7B3-E209-4D2E-BA9B-8B32C26CAB2C

P2860

Q35771163-0086CFF6-4C8F-4945-A035-267D9EDE2185

Q35771163-26E78EB2-A65E-4A18-BB51-E732E90B8CBE

Q35771163-2A35471A-843E-4E5E-A6E8-E56855ED2D27

Q35771163-2EB6F7F5-F268-4CBB-9EF3-8B9EE8A3497F

Q35771163-309352DC-88F0-41EA-BF0B-85DA37414450

Q35771163-35FE0CEE-15B4-4085-B9C7-B3E07C812D85

Q35771163-3B68D7FE-6340-4AF9-AC3C-9A893D42DB10

Q35771163-3DA1D775-C99F-488C-BD6A-2D27F70208BD

Q35771163-3E756CD4-910C-4BE1-AFD3-A255A30FB8EC

Q35771163-486A2292-ABA3-491F-9E9E-85456D6E75E7

P304

Q35771163-331E7A25-38BE-45AB-9652-1FEFED80298C

P31

Q35771163-EA6CAE41-AD89-463F-B41B-47004B57FF3C

P356

Q35771163-FA3CCAA1-E4EC-459C-B632-B00ED05E39BD

P433

Q35771163-F2241D5D-5064-478B-98C2-551DCF5C42F6

P478

Q35771163-D8C6CFCA-FBF2-4938-AE34-ED10B9179996

P577

Q35771163-31662940-F998-42F8-B559-2AAAF1514983

P698

Q35771163-F6BD692B-4D4B-40C4-922E-865BD7C2A586

P932

Q35771163-A592240B-4A26-4C62-8894-6A9B8D47C419

P356

P1433

Journal of Lipid Research

P1476

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

@en

P2093

Ashley B Irish

http://www.w3.org/2001/XMLSchema#string

Dick C Chan

http://www.w3.org/2001/XMLSchema#string

Doris T Chan

http://www.w3.org/2001/XMLSchema#string

Esther M M Ooi

http://www.w3.org/2001/XMLSchema#string

Gerald F Watts

http://www.w3.org/2001/XMLSchema#string

Gursharan K Dogra

http://www.w3.org/2001/XMLSchema#string

P Hugh R Barrett

http://www.w3.org/2001/XMLSchema#string

Theodore W K Ng

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein C-III: understanding an emerging cardiovascular risk factor

Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation

Carbamoylation of amino acids and proteins in uremia.

Peroxisome proliferator-activated receptors: from genes to physiology.

Reactive carbonyl compounds related uremic toxicity ("carbonyl stress").

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates

P304

794-800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M011163

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21297177

http://www.w3.org/2001/XMLSchema#string

P932

3284168

http://www.w3.org/2001/XMLSchema#string